$736 Million is the total value of SECTORAL ASSET MANAGEMENT INC's 104 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PODD | INSULET CORP | $7,643,000 | -25.1% | 96,360 | 0.0% | 1.04% | -4.2% | |
| OBSV | OBSEVA SA | $7,149,000 | -29.8% | 564,692 | 0.0% | 0.97% | -10.1% | |
| EVLO | EVELO BIOSCIENCES | $5,297,000 | +6.8% | 407,171 | 0.0% | 0.72% | +36.9% | |
| MGTX | MEIRAGTX HLDINGS PLC | $3,932,000 | -29.1% | 407,906 | 0.0% | 0.53% | -9.3% | |
| SAGE | SAGE THERAPEUTICS | $3,554,000 | -32.2% | 37,100 | 0.0% | 0.48% | -13.1% | |
| MTEM | MOLECULAR TEMPLATES | $1,414,000 | -25.1% | 350,000 | 0.0% | 0.19% | -4.0% | |
| TMO | THERMO FISHER SCI | $1,018,000 | -8.3% | 4,549 | 0.0% | 0.14% | +16.9% | |
| HCM | HUTCHISON CHINA MEsp adr | $730,000 | -28.3% | 31,628 | 0.0% | 0.10% | -8.3% | |
| BDX | BECTON DICKINSON | $679,000 | -13.7% | 3,015 | 0.0% | 0.09% | +9.5% | |
| RARE | ULTRAGENYX PHARMAC | $393,000 | -43.1% | 9,047 | 0.0% | 0.05% | -27.4% | |
| SRRA | SIERRA ONCOLOGY INC | $343,000 | 0.0% | 201,660 | 0.0% | 0.05% | +30.6% | |
| KALV | KALVISTA PHARMACEUTI | $347,000 | -10.6% | 17,551 | 0.0% | 0.05% | +14.6% | |
| SYK | STRYKER CORP | $324,000 | -11.7% | 2,066 | 0.0% | 0.04% | +12.8% | |
| CERS | CERUS CORP | $307,000 | -29.7% | 60,576 | 0.0% | 0.04% | -8.7% | |
| DERM | DERMIRA INC | $301,000 | -34.1% | 41,902 | 0.0% | 0.04% | -16.3% | |
| CHRS | COHERUS BIOSCIENCES | $253,000 | -45.2% | 27,987 | 0.0% | 0.03% | -30.6% | |
| KANG | IKANG HEALTHCARE Gsp adr | $235,000 | +13.0% | 11,513 | 0.0% | 0.03% | +45.5% | |
| RVNC | REVANCE THERAPEUTI | $226,000 | -19.0% | 11,234 | 0.0% | 0.03% | +3.3% | |
| BPMC | BLUEPRINT MEDICINES | $226,000 | -30.9% | 4,184 | 0.0% | 0.03% | -11.4% | |
| ZBH | ZIMMER BIOMET HLDS | $218,000 | -21.0% | 2,099 | 0.0% | 0.03% | +3.4% | |
| CCXI | CHEMOCENTRYX INC | $194,000 | -13.8% | 17,811 | 0.0% | 0.03% | +8.3% | |
| KURA | KURA ONCOLOGY INC | $166,000 | -19.8% | 11,800 | 0.0% | 0.02% | +4.5% | |
| ACRX | ACELRX PHARMACEUTI | $170,000 | -40.1% | 73,778 | 0.0% | 0.02% | -23.3% | |
| CTMX | CYTOMX THERAPEUTIC | $152,000 | -18.3% | 10,058 | 0.0% | 0.02% | +5.0% | |
| ATRS | ANTARES PHARMA INC | $129,000 | -18.9% | 47,280 | 0.0% | 0.02% | +5.9% | |
| MEIP | MEI PHARMA INC | $118,000 | -38.5% | 44,539 | 0.0% | 0.02% | -20.0% | |
| QTNT | QUOTIENT LTD | $108,000 | -18.8% | 17,649 | 0.0% | 0.02% | +7.1% | |
| AGLE | AEGLEA BIOTHERAPEU | $97,000 | -21.8% | 12,954 | 0.0% | 0.01% | 0.0% | |
| CYTK | CYTOKINETICS INC | $98,000 | -35.9% | 15,582 | 0.0% | 0.01% | -18.8% | |
| BLRX | BIOLINERX LTDsp adr | $87,000 | -59.0% | 198,297 | 0.0% | 0.01% | -47.8% | |
| ABEO | ABEONA THERAPEUTICS | $91,000 | -43.8% | 12,681 | 0.0% | 0.01% | -29.4% | |
| NABRIVA THERAPEUTICS | $56,000 | -45.6% | 38,255 | 0.0% | 0.01% | -27.3% | ||
| CDTX | CIDARA THERAPEUTICS | $60,000 | -46.4% | 25,447 | 0.0% | 0.01% | -33.3% | |
| MRNS | MARINUS PHARMACUTCLS | $48,000 | -71.4% | 16,800 | 0.0% | 0.01% | -61.1% | |
| TTPH | TETRAPHASE PHARMAC | $45,000 | -59.1% | 39,821 | 0.0% | 0.01% | -50.0% | |
| CRVS | CORVUS PHARMACEUTI | $46,000 | -57.4% | 12,594 | 0.0% | 0.01% | -45.5% | |
| CLSD | CLEARSIDE BIOMEDIC | $28,000 | -82.5% | 25,959 | 0.0% | 0.00% | -76.5% | |
| PLX | PROTALIX BIOTHERA | $31,000 | -56.9% | 99,667 | 0.0% | 0.00% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMAC INC | 42 | Q3 2023 | 6.7% |
| PTC THERAPEUTICS INC | 42 | Q3 2023 | 2.7% |
| DR REDDYS LABS LTD | 42 | Q3 2023 | 2.0% |
| GILEAD SCIENCES INC | 38 | Q3 2023 | 8.4% |
| INCYTE CORPORATION | 38 | Q3 2023 | 5.2% |
| VERTEX PHARMACEUTICL | 38 | Q3 2023 | 6.0% |
| AMICUS THERAPEUTICS INC | 37 | Q3 2023 | 6.6% |
| PFIZER INC | 35 | Q3 2023 | 6.3% |
| MERCK & CO. INC | 34 | Q3 2023 | 6.4% |
| MEDTRONIC PLC | 33 | Q3 2023 | 4.4% |
View SECTORAL ASSET MANAGEMENT INC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aprea Therapeutics, Inc. | February 12, 2021 | 163,681 | 0.8% |
| LA JOLLA PHARMACEUTICAL CO | February 13, 2020 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 13, 2018 | 1,426,862 | 4.4% |
| Advaxis, Inc. | February 10, 2017 | 690,074 | 1.7% |
| AMICUS THERAPEUTICS INC | February 10, 2017 | 5,100,198 | 3.6% |
| OncoMed Pharmaceuticals Inc | February 12, 2016 | ? | ? |
| IRONWOOD PHARMACEUTICALS INC | February 13, 2015 | ? | ? |
| SEQUENOM INC | February 12, 2014 | ? | ? |
| INCYTE CORP | February 11, 2014 | 1,185,260 | 0.7% |
| INTERMUNE INC | February 11, 2014 | ? | ? |
View SECTORAL ASSET MANAGEMENT INC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2023-02-10 |
View SECTORAL ASSET MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.